Skip to content

Combined Molecular Microscopy for Therapy and Personalized Medication in Rare Anaemias Treatments

Combined Molecular Microscopy for Therapy and Personalized Medication in Rare Anaemias Treatments - CoMMiTMenT

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON41732
Enrollment
80
Registered
2015-04-14
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anaemia herideritarty hemolytic anaemia

Interventions

None listed

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
12 Years to 99 Years

Inclusion criteria

Inclusion criteria: Know and unknown cause of (heriditary) hemolytic anaemia, low Hb, high plasma hemoglobin and/or or family member to be known with (heriditary) hemolytic anaemia

Exclusion criteria

Exclusion criteria: Transfusion received within 90 days

Design outcomes

Primary

MeasureTime frame
o Red blood cell hematology parameters; cytology and biochemistry o Red blood cell morphology o Quantity and size distribution of (RBC) microvesicles o Eosin-5-maleimide (EMA) binding on surface of red blood cells o Intracellular Ca2+, Na+ and K+ levels o Na+ uptake and K leak by red blood cells o Activity of transporters NHE, NKCC, Na/K-ATPase, Gardos channes and other channels/conductance o Conductance and patch-clamp measurements of red blood cells o CD47 presentation o 2,3-DPG measurement o Band 3 clustering o ATP concentration o Glutathione measurement: ratio between GSH/GSSG o Osmotic fragility o Density o Enzyme activity o Osmotic gradient ektacytometry (LoRRca MaxSis) o Deformability (LoRRca MaxSis) o PS exposure o DNA analysis for candidate ion channels by PCR and Next Generation Sequencing: Band3, spectrin, ankyrin, protein 4.2, EPB72/STOM, KCNN4, TRPC6, GRIN1, GRIN2A, GRIN2C, GRIN2D, GRIN3A, GRIN3B, SLC9A1, ATP11C, XK, AQP1, AQP3, ATP1A2, ACHE, CAII, SLC16A1, VDAC3, TSPO, SLC25A4, CLCN2, PIEZO1

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)